- Rating
- 1
- Confidence
- 3
- Informativeness
- 3
- Presentation
- 3
- Soundness
- 1
Read review
Paper summary
DynamicVC extends VCWorld with SimContext, which converts scDFM-predicted expression states, generative-path features, and consistency information into evidence for an LLM to predict differential gene expression under drug perturbations. Experiments cover held-out drugs across five cell lines, different LLM backbones, and alternative evidence configurations. The authors report improvements over VCWorld, but the biological interpretation and independent contribution of the dynamic evidence remain insufficiently established.
Critical strengths
-
The paper presents a concrete framework for combining numerical perturbation predictions with LLM-based reasoning. SimContext makes simulation outputs accessible to the LLM through structured statistics, rules, and text templates.
-
The experiments cover multiple LLM backbones and cell lines, and compare different evidence configurations. The reported improvements suggest that incorporating simulation-derived information can benefit prediction.
Critical weaknesses
-
The biological meaning of the generative trajectory is unclear. scDFM generates expression states from noise, so intermediate states do not necessarily represent a biological transition from control to perturbed cells. Features such as “delay” and “reversal” may reflect the generative process rather than actual response dynamics. The paper does not establish why these features should be interpreted as biological evidence, weakening the central motivation of trajectory-grounded reasoning.
-
The contribution of dynamic evidence is not convincingly isolated. The endpoint-only versus dynamic comparison is reported for scDFM, but not for CellFlow. The results therefore do not establish whether intermediate states provide consistent gains beyond endpoint predictions or whether the reported improvement depends on the particular generative model.
-
Inconsistencies in reported metrics raise concerns about result reliability. The class-specific metrics in Appendix Table C.1 imply balanced-accuracy values for STATE and X-Cell that differ from those reported in Table 1 under the stated aggregation convention. These discrepancies are not explained, making the affected baseline comparisons difficult to verify and raising concerns about reproducibility.
Questions for authors
-
What biological information do the intermediate generative states and features such as “delay” and “reversal” capture beyond the final predicted expression state? What assumptions justify interpreting them as evidence of perturbation dynamics rather than artifacts of the generation process?
-
Could the authors provide matched endpoint-only versus dynamic comparisons for CellFlow and, if feasible, other generative models? Without these comparisons, it is difficult to determine whether the benefit of dynamic evidence generalizes beyond scDFM.
-
Could the authors reconcile the balanced-accuracy discrepancies between Table 1 and Appendix Table C.1, clarify the metric definitions and aggregation procedures, and provide corrected results if necessary? Do these corrections affect the paper’s conclusions?